The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer

Jiangfeng Wang, Jianqiang Li, Lei Cai, Sheng Chen, Youhua JiangAnnals 2021 · DOI

Abstract

The outcomes of PD-1 inhibitor with chemotherapy as a novel treatment for stage IIIA NSCLC in the neoadjuvant setting are satisfactory with respect to the high R0 resection rate and low toxicity profile. Prospective comparative and longer follow-up trials are needed to confirm the long-term outcomes of this novel treatment and to reach definitive conclusions.
BibTeX
@article{wang2021safety,
  author = {Jiangfeng Wang and Jianqiang Li and Lei Cai and Sheng Chen and Youhua Jiang},
  title = {{The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer}},
  journal = {Annals},
  year = {2021},
  doi = {10.21037/atm-21-670},
}

Loading related content...

Figure